2nd diagnosis and management of menopause Guideline Development Group meeting
Wednesday 23rd October 2013 10am – 4.00pm at RCPCH

Present:
Mary Ann Lumsden (MAL) GDG Chair
Terry Aspray (TA) Physician (with a special interest in bone health)
Claire Bowring (CB) Lay member
Melanie Davies (MD) Consultant gynaecologist
Sally Hope (SH) GP
Prunella Neale (PN) Practice nurse
Tony Parsons (TP) Community gynaecologist
Imogen Shaw (IH) GP
Debby Holloway (DH) Specialist nurse
Sara Moger (SM) Lay member

NCC staff:
David Bevan (DB) Project manager
Hannah-Rose Douglas (HRD) Associate director and team leader
David James (DJ) Clinical director
Hugh McGuire (HMG) Senior research fellow
Katie Webster (KW) Research associate

In attendance:
Sarah Dundson (SD) Guidelines Commissioning Manager, NICE
Jessica Simms (JF) PIP project manager, NICE

Apologies
Nick Panay (NP) Consultant gynaecologist

1. Welcome, housekeeping, introductions and apologies
MAL welcomed the group to the second meeting of this guideline development group (GDG) and introduced herself as the Chair. MAL introduced SM and DH to the group.

2. Declarations of interest
MD declared that she sits on the European Society for Human Reproduction and Embryology (ESHRE) guideline group for premature ovarian insufficiency (POI).

SM declared that she is the chief executive of the British Menopause Society (BMS)

3. Introduction to Health Economics
HRD gave a presentation on the role of health economics in the guideline development process. After the presentation, the group had an opportunity to ask questions.
4. **Introduction to the scope and review questions**
MAL and HRD presented the review questions outlined in the scope and the approach taken to develop a review question’s protocol. After the presentation, the group had an opportunity to ask questions.

5. **Presentation of review on endocrine markers for the diagnosis of peri-and post-menopause**
KW introduced the evidence for the GDG to consider how endocrine markers can be used for the diagnosis of the peri-and post-menopause.

**Break**

6. **Developing a review protocol**
The GDG worked in smaller topic groups to discuss the guideline’s protocols.

**Lunch**

7. **Developing a review protocol (cont’d)**
The GDG worked in smaller topic groups to discuss the guideline’s protocols and fed back their suggestions to rest of the group.

**Break**

8. **Developing a review protocol (cont’d)**
The GDG worked in smaller topic groups to discuss the guideline’s protocols and fed back their suggestions to rest of the group.

9. **Any other business**
There was no other business. MAL thanked the participants for attending and closed the meeting.
Welcome, housekeeping, introductions and apologies
MAL welcomed the group to the second meeting of this guideline development group (GDG) and introduced herself as the Chair. MAL introduced RH and MH to the group.

No new declarations of interest were made.

DJ recapped the first day of the GDG and introduced the protocols for the treatment of shorter-term menopausal symptoms.

Protocol - What is the effectiveness (including risks and benefits) of different therapies compared with placebo and each other for the relief of individual menopause-related psychological symptoms, musculoskeletal symptoms and altered sexual function?
HMG presented the draft review protocol: What is the effectiveness (including risks and benefits) of different therapies compared with placebo and each other for the relief of individual menopause-related psychological symptoms, musculoskeletal symptoms and altered sexual function? The group then discussed the protocol and finalised the content.

Break

14. Introduction to the network meta-analysis
SDs introduced the methodology for completing a network meta-analysis. After the presentation, the group had an opportunity to ask questions.

Lunch

15. Protocol - What is the effectiveness (including risks and benefits) of different therapies compared with placebo and each other for the relief of individual menopause-related vasomotor symptoms?
HMG presented the draft review protocol: What is the effectiveness (including risks and benefits) of different therapies compared with placebo and each other for the relief of individual menopause-related vasomotor symptoms? The group then discussed the protocol and finalised the content.

Break

16. Any other business
There was no other business. MAL thanked the participants for attending and closed the meeting.

Signed:…………………………………………………………………. Date:…………………………..
Mary Ann Lumsden, GDG Chair

Signed:…………………………………………………………………. Date:…………………………..
David James, Clinical Director (Women’s Health)